292 related articles for article (PubMed ID: 29489701)
1. Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.
Yang Y; Yan S; Tian H; Bao Y
Medicine (Baltimore); 2018 Mar; 97(9):e9994. PubMed ID: 29489701
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
Liang B; Zhong L; He Q; Wang S; Pan Z; Wang T; Zhao Y
Med Sci Monit; 2015 Nov; 21():3555-63. PubMed ID: 26576628
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis.
Huang Z; Liu F
Tumour Biol; 2014 Aug; 35(8):7459-65. PubMed ID: 24789274
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of serum macrophage inhibitory cytokine-1 in pancreatic cancer: a meta-analysis and meta-regression analysis.
Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
DNA Cell Biol; 2014 Jun; 33(6):370-7. PubMed ID: 24592997
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer.
Zhang Y; Jiang L; Song L
Minerva Med; 2016 Feb; 107(1):62-9. PubMed ID: 26824636
[TBL] [Abstract][Full Text] [Related]
7. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort.
O'Neill RS; Emmanuel S; Williams D; Stoita A
World J Gastroenterol; 2020 Apr; 26(14):1660-1673. PubMed ID: 32327914
[TBL] [Abstract][Full Text] [Related]
8. Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis.
Cao S; Hu Y; Gao X; Liao Q; Zhao Y
PLoS One; 2016; 11(11):e0166406. PubMed ID: 27835676
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer.
Mohamed AA; Soliman H; Ismail M; Ziada D; Farid TM; Aref AM; Al Daly ME; Abd Elmageed ZY
Pancreatology; 2015; 15(1):34-9. PubMed ID: 25464937
[TBL] [Abstract][Full Text] [Related]
10. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
11. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.
Kaur S; Chakraborty S; Baine MJ; Mallya K; Smith LM; Sasson A; Brand R; Guha S; Jain M; Wittel U; Singh SK; Batra SK
PLoS One; 2013; 8(2):e55171. PubMed ID: 23383312
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a meta-analysis.
Chen G; Liu S; Zhao Y; Dai M; Zhang T
Pancreatology; 2013; 13(3):298-304. PubMed ID: 23719604
[TBL] [Abstract][Full Text] [Related]
13. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.
Gui JC; Yan WL; Liu XD
Clin Exp Med; 2014 May; 14(2):225-33. PubMed ID: 23456571
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis.
Zhao B; Zhao B; Chen F
Eur J Gastroenterol Hepatol; 2022 Sep; 34(9):891-904. PubMed ID: 35913776
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of Serum IgG4 for IgG4-Related Disease: A PRISMA-compliant Systematic Review and Meta-analysis.
Hao M; Liu M; Fan G; Yang X; Li J
Medicine (Baltimore); 2016 May; 95(21):e3785. PubMed ID: 27227950
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs as novel biomarkers for the differentiation of malignant versus benign thyroid lesions: a meta-analysis.
Zhou GJ; Xiao M; Zhao LN; Tang JG; Zhang L
Genet Mol Res; 2015 Jul; 14(3):7279-89. PubMed ID: 26214406
[TBL] [Abstract][Full Text] [Related]
18. The Accuracy of Single MicroRNAs in Peripheral Blood to Diagnose Ovarian Cancer: An Updated Meta-Analysis.
Cui Y; Hong S; Zhu X
Dis Markers; 2020; 2020():1075942. PubMed ID: 32025275
[TBL] [Abstract][Full Text] [Related]
19. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of S100P for pancreatic cancer: a meta-analysis.
Hu H; Zhang Q; Huang C; Shen Y; Chen X; Shi X; Tang W
Tumour Biol; 2014 Oct; 35(10):9479-85. PubMed ID: 25123266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
